JP7097667B2 - 無担体生物活性タンパク質ナノ構造体 - Google Patents

無担体生物活性タンパク質ナノ構造体 Download PDF

Info

Publication number
JP7097667B2
JP7097667B2 JP2016517553A JP2016517553A JP7097667B2 JP 7097667 B2 JP7097667 B2 JP 7097667B2 JP 2016517553 A JP2016517553 A JP 2016517553A JP 2016517553 A JP2016517553 A JP 2016517553A JP 7097667 B2 JP7097667 B2 JP 7097667B2
Authority
JP
Japan
Prior art keywords
protein
cells
cancer
cell
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016517553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533344A5 (enExample
JP2016533344A (ja
Inventor
リー・タン
ダレル・ジェイ・アーバイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2016533344A publication Critical patent/JP2016533344A/ja
Publication of JP2016533344A5 publication Critical patent/JP2016533344A5/ja
Application granted granted Critical
Publication of JP7097667B2 publication Critical patent/JP7097667B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
JP2016517553A 2013-09-27 2014-09-26 無担体生物活性タンパク質ナノ構造体 Expired - Fee Related JP7097667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361883503P 2013-09-27 2013-09-27
US61/883,503 2013-09-27
PCT/US2014/057789 WO2015048498A2 (en) 2013-09-27 2014-09-26 Carrier-free biologically-active protein nanostructures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020109309A Division JP7272664B2 (ja) 2013-09-27 2020-06-25 無担体生物活性タンパク質ナノ構造体

Publications (3)

Publication Number Publication Date
JP2016533344A JP2016533344A (ja) 2016-10-27
JP2016533344A5 JP2016533344A5 (enExample) 2017-11-09
JP7097667B2 true JP7097667B2 (ja) 2022-07-08

Family

ID=51795741

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016517553A Expired - Fee Related JP7097667B2 (ja) 2013-09-27 2014-09-26 無担体生物活性タンパク質ナノ構造体
JP2020109309A Active JP7272664B2 (ja) 2013-09-27 2020-06-25 無担体生物活性タンパク質ナノ構造体
JP2023069170A Pending JP2023103260A (ja) 2013-09-27 2023-04-20 無担体生物活性タンパク質ナノ構造体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020109309A Active JP7272664B2 (ja) 2013-09-27 2020-06-25 無担体生物活性タンパク質ナノ構造体
JP2023069170A Pending JP2023103260A (ja) 2013-09-27 2023-04-20 無担体生物活性タンパク質ナノ構造体

Country Status (6)

Country Link
US (6) US9603944B2 (enExample)
EP (2) EP3049114B1 (enExample)
JP (3) JP7097667B2 (enExample)
CA (2) CA3191031A1 (enExample)
ES (1) ES2904276T3 (enExample)
WO (1) WO2015048498A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
AU2016305087B2 (en) * 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN109715196A (zh) * 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11123441B2 (en) * 2016-10-04 2021-09-21 The Trustees Of The University Of Pennsylvania Methods and compositions for drug delivery
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
CA3074826A1 (en) * 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
EP3678704A4 (en) * 2017-09-05 2021-09-01 Torque Therapeutics, Inc. REVERSIBLE LINKS AND THEIR USE
JP2022500034A (ja) 2018-09-10 2022-01-04 トルク セラピューティクス， インコーポレイテッド 抗原特異的ｔリンパ球ならびに抗原特異的ｔリンパ球を作製および使用する方法
AU2020253356A1 (en) * 2019-03-29 2021-10-28 Torque Therapeutics, Inc. Immunotherapeutic compositions and use thereof
FR3099052B1 (fr) * 2019-07-23 2022-03-25 Univ Franche Comte Structures particulaires à base de nanoparticules d’or, leurs procédés de préparation et leurs utilisations dans le traitement des tumeurs solides
EP3795172A1 (en) 2019-09-20 2021-03-24 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Polymer or polycondensate based on peptide, linker and optionally other monomers and method for preparing the same
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
CN112125832B (zh) * 2020-08-12 2022-09-20 北京大学 刺突蛋白受体结合结构域纳米凝胶及其制备方法与应用
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN112891556B (zh) * 2021-02-01 2023-03-03 浙江大学医学院附属第一医院 一种单抗类药物口服纳米凝胶及其制备方法
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN115746044A (zh) * 2022-09-27 2023-03-07 大连理工大学 一类含有链中柔性链段和脲键的硅烷偶联剂及其制备方法及其制备方法
US20260234258A1 (en) 2022-10-20 2026-08-13 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007131568A (ja) 2005-11-09 2007-05-31 Nippon Seiyaku Kogyo Kk 免疫賦活剤及びこれを含有する免疫賦活性飲食物
JP2007528726A (ja) 2004-02-27 2007-10-18 インセルム（アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
JP2013511539A (ja) 2009-11-18 2013-04-04 ネクター セラピューティックス ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147633T1 (de) 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
JPH03244601A (ja) 1990-02-22 1991-10-31 Masuko Suzuki マンナンと癌細胞分化誘導体の複合体、その製法及び抗癌剤
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
CA2065658A1 (en) 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US5753261A (en) 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5464629A (en) 1993-11-16 1995-11-07 Georgetown University Method of forming hydrogel particles having a controlled size using liposomes
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
IN190388B (enExample) 1997-10-01 2003-07-26 Biomira Usa Inc
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6319715B1 (en) 2000-04-21 2001-11-20 Cornell Research Foundation, Inc. Method of enhancing the delivery of nucleic acids using silica nanoparticles
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質ａおよび他の炭水化物リガンド類似体
AU2003300043A1 (en) 2002-10-10 2004-05-04 Elizabeth Chambers Carriers attached to blood cells
US8192485B2 (en) * 2002-11-13 2012-06-05 The United States of America, as represented by the Department of Veterens Affairs Reversible hydrogel systems and methods therefor
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7223544B2 (en) 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE102004054536A1 (de) 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
US20070148246A1 (en) 2005-08-11 2007-06-28 Dan Luo Nucleic Acid-Based Matrixes
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
JP2009508936A (ja) 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー 活性物質の標的化送達用ナノ粒子
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CA2601803A1 (en) 2006-01-13 2007-07-19 Riken Preventive or therapeutic agent and method for immune disease
CA2643826A1 (en) 2006-02-27 2008-06-12 Paul A. Wender Compositions and methods for transport of molecules with enhanced release properties across biological barriers
US8367051B2 (en) * 2006-10-09 2013-02-05 Carnegie Mellon University Preparation of functional gel particles with a dual crosslink network
CA2705797A1 (en) 2007-11-14 2009-05-22 The Regents Of The University Of California Sterol-modified amphiphilic lipids
JP2009149526A (ja) 2007-12-18 2009-07-09 Tokyo Medical & Dental Univ サイトカイン−ナノゲル複合体を含む皮下注射又は筋肉内注射徐放製剤
WO2009134866A2 (en) 2008-04-29 2009-11-05 The Brigham And Women's Hospital, Inc. Cell membrane engineering
WO2010059253A2 (en) 2008-11-24 2010-05-27 Massachusets Institute Of Technology Methods and compositions for localized agent delivery
EP2406173A4 (en) 2009-03-09 2016-04-06 Univ California SINGLE PROTEIN NANOCAPSULES FOR PROTEIN RELIEF WITH LONG-TERM EFFECT
CA2754896C (en) 2009-03-09 2017-11-28 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20100324124A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
US20100323018A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
SG184127A1 (en) 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20110229556A1 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
WO2012024396A2 (en) 2010-08-17 2012-02-23 Rutgers, The State University Of New Jersey Compositions and methods for delivering nucleic acid molecules and treating cancer
EP2616103A1 (en) 2010-09-16 2013-07-24 The University of North Carolina At Chapel Hill Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
US20140081012A1 (en) 2011-02-15 2014-03-20 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
WO2012142410A2 (en) 2011-04-15 2012-10-18 The Regents Of The University Of California Redox responsive polymeric nanocapsules for protein delivery
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
JP2013173689A (ja) 2012-02-24 2013-09-05 Univ Of Tsukuba 高分子化ニトロキシドラジカル化合物と非ステロイド性抗炎症薬の複合体
US20130337471A1 (en) 2012-06-14 2013-12-19 Emory University Cell identification with nanoparticles, compositions and methods related thereto
US9149535B2 (en) * 2012-06-28 2015-10-06 University Of South Carolina Polymers and the preparation of nanogel drug cocktails
FR3004106B1 (fr) 2013-04-05 2016-08-05 Oreal Composition contenant des particules composites filtrant les radiations uv de taille moyenne superieure a 0,1μm et des particules d'aerogel de silice hydrophobes
EP3650038A1 (en) 2013-06-19 2020-05-13 Massachusetts Institute of Technology In vivo targeting of cells with ligand-conjugated particles
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
AU2016305087B2 (en) * 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US10933660B2 (en) 2017-02-01 2021-03-02 Hewlett-Packard Development Company, L.P. Output tension zones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528726A (ja) 2004-02-27 2007-10-18 インセルム（アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
JP2007131568A (ja) 2005-11-09 2007-05-31 Nippon Seiyaku Kogyo Kk 免疫賦活剤及びこれを含有する免疫賦活性飲食物
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
JP2013511539A (ja) 2009-11-18 2013-04-04 ネクター セラピューティックス ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ Ｂｉｏｐｈｙｓｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ，２００８，Ｖｏｌ．３６７，ｐ．３３０－３３５
ＢＩＯＣＯＮＪＵＧＡＴＥ ＣＨＥＭＩＳＴＲＹ，２０１２，Ｖｏｌ．２３，Ｎｏ．７，ｐ．１４５２－１４６２
ＮＡＴＵＲＥ ＭＥＤＩＣＩＮＥ，２０１０，Ｖｏｌ．１６，Ｎｏ．９，ｐ．１０３５－１０４１
Ｐｏｌｙｍｅｒ Ｃｈｅｍｉｓｔｒｙ（ＰＡＰＥＲ），２０１３，Ｖｏｌ．４，Ｎｏ．８，ｐ．２４６４－２４６９
Ｓｏｆｔ Ｍａｔｔｅｒ，２０１２，Ｖｏｌ．８，ｐ．２６４４－２６５０
最新医学，２００９，Ｖｏｌ．６４，Ｎｏ．１１，ｐ．５８－６４

Also Published As

Publication number Publication date
JP2023103260A (ja) 2023-07-26
US20150110740A1 (en) 2015-04-23
WO2015048498A9 (en) 2016-01-28
US10226510B2 (en) 2019-03-12
CA2925304C (en) 2023-04-18
US20200016238A1 (en) 2020-01-16
US11529392B2 (en) 2022-12-20
US20230277626A1 (en) 2023-09-07
EP3049114A2 (en) 2016-08-03
ES2904276T3 (es) 2022-04-04
US10588942B2 (en) 2020-03-17
CA3191031A1 (en) 2015-04-02
JP2020158537A (ja) 2020-10-01
EP4043036A1 (en) 2022-08-17
US10357544B2 (en) 2019-07-23
EP3049114B1 (en) 2021-11-10
US9603944B2 (en) 2017-03-28
WO2015048498A2 (en) 2015-04-02
WO2015048498A3 (en) 2015-07-23
CA2925304A1 (en) 2015-04-02
US20190083576A1 (en) 2019-03-21
JP7272664B2 (ja) 2023-05-12
US20170196938A1 (en) 2017-07-13
JP2016533344A (ja) 2016-10-27
US20200360482A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
JP7272664B2 (ja) 無担体生物活性タンパク質ナノ構造体
Luo et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy
JP6887685B2 (ja) ナノ粒子の細胞表面共役
Meng et al. In situ activated NK cell as bio‐orthogonal targeted live‐cell nanocarrier augmented solid tumor immunotherapy
US12370255B2 (en) Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
Li et al. A" trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice
CN100542612C (zh) 类脂化糖胺聚糖颗粒及其在诊断和治疗用药物和基因传递中的应用
US10350298B2 (en) Immunomodulatory protein constructs with a helical polymeric backbone
JP2016533344A5 (enExample)
CN116390754A (zh) 用于过继细胞治疗的可注射水凝胶
WO2023104137A1 (zh) 肿瘤抗原响应性活细胞纳米药物背包的制备方法及应用
HK40079405A (en) Carrier-free biologically-active protein nanostructures
US20240042054A1 (en) Hydrogel compositions comprising gasdermin d and an escrt inhibitor and methods of use thereof
CN114149941B (zh) 一种表面结合靶向配体的细菌及其应用
채세열 Development of therapeutic protein carrier using porous silica nanomaterials
CN107778378A (zh) 甘露糖修饰壳聚糖硬脂酸嫁接物及制备和应用
CN121606713A (zh) 一种t细胞协同治疗体系及其制备方法与应用
CN121015860A (zh) 一种疫苗及其制备方法和应用
Mottas Nanoparticles for Lymph Node Delivery of Antigenic Peptides Or Immunostimulants to Improve Cancer Immunotherapy
JP2014198671A (ja) 腫瘍ワクチン効果を有する複合体及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200625

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200721

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200728

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201002

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201006

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210316

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210427

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210706

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20211116

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20211124

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20211124

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20211124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220426

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220531

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220628

R150 Certificate of patent or registration of utility model

Ref document number: 7097667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees